Drug treatment of Duchenne muscular dystrophy: Available evidence and perspectives

Acta Myologica

Volumn 31, Issue MAY, 2012, Pages 4-8

  De Los Angeles Beytía, Maria ^a   Vry, Julia ^a   Kirschner, Janbernd ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Clinical trials; Drug treatment; Duchenne muscular dystrophy

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ATALUREN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DEFLAZACORT; DYSTROPHIN; GENTAMICIN; MYOSTATIN; PREDNISONE; UTROPHIN; VITAMIN D;

ACNE; BEHAVIOR DISORDER; BODY HEIGHT; BODY WEIGHT; CATARACT; CELL CULTURE; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GASTROINTESTINAL DISEASE; GENE MUTATION; GENE THERAPY; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; LIFE EXPECTANCY; LOW DRUG DOSE; MOON FACE; NONHUMAN; PUBERTY DISORDERS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

AMINOGLYCOSIDES; GENE THERAPY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCULAR DYSTROPHY, DUCHENNE; MYOSTATIN; OXADIAZOLES; PREDNISONE; PREGNENEDIONES; UTROPHIN;

EID: 84861716968     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Poysky J. Behavior patterns in Duchenne muscular dystrophy: report on the Parent Project Muscular Dystrophy behavior workshop 8-9 of December 2006, Philadelphia, USA. Neuromuscul Disord 2007;17:986-94. (Pubitemid 350141665)
2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
3. O'Brien KF, Kunkel LM. Dystrophin and muscular dystrophy: past, present, and future. Mol Genet Metab 2001;74:75-88. (Pubitemid 32955149)
4. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2:731-40. (Pubitemid 37443515)
5. Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. 2011. Mol Ther 2011;19:830-40.
6. Nelson SF, Crosbie R, Miceli MC, et al. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009;22:532-8.
7. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008;93:986-90.
8. Moxley RT, Pandya S, Ciafoli E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroids treatment: implications for management. J Child Neurol 2010;25:1116-29.
9. Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8 year follow-up. Pediatr Neurol 2008;38;200-6. (Pubitemid 351221232)
10. Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20. (Pubitemid 40082930)
11. Angelini G. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007;36:424-35.
12. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;1:CD003725.
13. Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfuntion in Duchenne muscular dystrophy. Neuromuscul Disord 2008;18:365-70.
14. Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy - the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007;17:470-5. (Pubitemid 46795560)
15. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68:1607-13. (Pubitemid 46717986)
16. Griggs RC, Moxley RT 3rd, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43:520-7. (Pubitemid 23088485)
17. Kirschner J, Schessl J, Schara U, et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 2010;9:1053-9.
18. Mendell JR, Rodino-Klapac LR, Malik V. Molecular therapeutic strategies targeting Duchenne muscular dystrophy. J Child Neurol 2010;25:1145-8.
19. Arechavala-Gomeza V, Kinali M, Feng L, et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 2010;20:295-301.
20. Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005;102:198-203. (Pubitemid 40094452)
21. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677-86.
22. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;364:1513-22.
23. Patridge T. The potential of exon skipping for the treatment for Duchenne muscular dystrophy. J Child Neurol 2010,25:1165-70.
24. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 2010;1798:2296-303.
25. Malerba A, Sharp PS, Graham IR, et al. Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther 2011;19:345-54.
26. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009;8:918-28.
27. Neri M, Torelli S, Brown S, et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 2007;17:913-8. (Pubitemid 350137731)
28. Politano L, Nigra G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003;22:15-21. (Pubitemid 36966404)
29. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49:706-11. (Pubitemid 32530236)
30. Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced rea through of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010;67:771-80.
31. Finkel R, Wong B, Bushby K, et al. Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD). Neuromuscul Disord 2010;20:656.
32. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63:561-71.
33. Chaubourt E, Fossier P, Baux G, et al. Heregulin ameliorates the dystrophic phenotype in mdx mice. Acad Sci USA 2004;101:13856-60.
34. Krag TO, Bogdanovich S, Jensen CJ, et al. Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc Natl Acad Sci USA 2004;101:13856-60. (Pubitemid 39298497)
35. Quinlivan R, Roper H, Davie M, et al. Report of Muscular Dystrophy Campaign funded workshop Birmingham, UK, Januar 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005;15:72-9. (Pubitemid 41556636)
36. Bachrach LK. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord 2005;15:86-7. (Pubitemid 41556638)